Hello,
This is probably a very naive question, but I have a hard time explaining this difference in results, and thus deciding what is the best strategy to adopt.
I am analyzing mice gut microbiome data (16S and WGS) with Maaslin3. I have a Treatment variable for which I have a Control group and multiple doses tested. I first wanted to make sure the compound had an impact on the gut microbiome. To do that, my naive strategy was to subset my data to keep only the control samples and the samples who had the highest dose. The rationale behind this subsetting was to reduce the number of test by reducing the number of features, as we keep only taxa present in at least x samples of our subsets (typically between 2 and 5 samples), to increase statistical power. This type of analysis could not select any taxa associated with the treatment, which lead us to explore other DA methods like ANCOM-BC or older methods like Lefse, because we could see, visually, a lot of differences, but our mice groups being very small, we figured that maybe Maaslin was too stringent.
Because we had different doses, I later decided to test whether there were a dose-effect, despite the lack of significant results of our first analysis. I conducted 2 analyses : 1- each dose was compared to the Control (Taxa ~ Treatment + (1|Cage)) and 2- each dose was compared to the prior dose (Taxa ~ ordered(Treatment) + (1|Cage)). To my surprise, and even though I had twice as many taxa tested in this analysis, several taxa were now selected as significantly associated to the highest dose, for both analyses. I have a hard time understanding what leads to this difference, and how, even though we significantly increased the number of tests, we have better statistical power at the end.
Thank you for your help
Have a nice day